Skip to main content

Advertisement

SpringerLink
Log in

A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032)

  • ASO Research Letter
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mowery YM, Ballman KV, Riedel RF, et al. SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma. Journal of Clinical Oncology. 2018;36(15):588. https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS11588.

    Article  Google Scholar 

  2. Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. The Lancet Oncology. 2017;18(11):1493–501. https://doi.org/10.1016/s1470-2045(17)30624-1.

    Article  CAS  Google Scholar 

  3. Burgess MA, Bolejack V, Schuetze S, et al. Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts. Journal of Clinical Oncology. 2019;37(15):11015–11015. https://doi.org/10.1200/JCO.2019.37.15_suppl.11015.

    Article  Google Scholar 

  4. Italiano A, Bellera C, D’Angelo S. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials. Journal of Hematology & Oncology. 2020;13(1):55. https://doi.org/10.1186/s13045-020-00891-5.

    Article  CAS  Google Scholar 

  5. Baldi GG, Gronchi A, Tazzari M, Stacchiotti S. Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumor. Expert Review of Anticancer Therapy. 2022;2:1–13. https://doi.org/10.1080/14737140.2022.2065986.

    Article  CAS  Google Scholar 

  6. Keung EZ, Tsai JW, Ali AM, et al. Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. Oncoimmunology. 2018;7(2):e1385689. https://doi.org/10.1080/2162402x.2017.1385689.

    Article  Google Scholar 

Download references

Acknowledgments

The SU2C-SARC032 trial is made possible by collaborative efforts between the Stand Up to Cancer (SU2C) foundation and the Sarcoma Alliance for Research through Collaboration (SARC), a non-profit cancer research organization. SARC and the Merck Sharp & Dohme LLC groups are the primary study sponsors for this trial. Conflict of interest statements by engaged authors have been provided.

Author information

Authors and Affiliations

  1. Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

    Areeba Saif MD, Emily A. Verbus MD, Amber Leila Sarvestani MD, Martha E. Teke MD, Jacob Lambdin MD & Jonathan M. Hernandez MD

  2. Radiation Oncology, Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC, USA

    David G. Kirsch MD, PhD

Authors
  1. Areeba Saif MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emily A. Verbus MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amber Leila Sarvestani MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martha E. Teke MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jacob Lambdin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jonathan M. Hernandez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. David G. Kirsch MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jonathan M. Hernandez MD or David G. Kirsch MD, PhD.

Ethics declarations

Disclosures

DGK has received research funding from XRAD Therapeutics, Bristol Myers Squibb, Varian Medical Systems, Merck Sharp and Dohme LLC. DGK owns stock and is on the scientific advisory board of Lumicell, Inc., which is commercializing intraoperative imaging technology. DGK is a cofounder of XRAD Therapeutics, which is developing radiosensitizers. The other co-authors report no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 105 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saif, A., Verbus, E.A., Sarvestani, A.L. et al. A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032). Ann Surg Oncol 30, 683–685 (2023). https://doi.org/10.1245/s10434-022-12762-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-12762-z

Search

Navigation